Variables Associated With Poor Clinical Outcomes in Patients With Serious Fluconazole Non-Susceptible Candida Species Infections
- 23 March 2026
- journal article
- research article
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 60 (12) , 1182-1188
Abstract
Background: Antifungal resistance among Candida species has become increasingly prevalent in recent years. Objectives: This study aims to identify independent predictors for poor outcomes associated with serious clinical infections caused by fluconazole non-susceptible Candida sp. across the Veterans Health Administration. Methods: This retrospective, observational, nationwide analysis included adults admitted to any Veterans Affairs Medical Center (VAMC) between January 1, 2009, and September 30, 2024, with positive cultures (or rapid diagnostic test) for Candida sp. from otherwise-sterile sites. Multivariate logistic regression assessed associations with the 30-day mortality in patients with these Candida sp. infections, regardless of fluconazole susceptibility. Results: Eligible cases were found from 1613 patients with 1651 culture episodes from otherwise-sterile sites detecting Candida sp. with available fluconazole susceptibility data. Non-susceptible Candida sp. was discovered in 261 of these episodes. Independent variables associated with 30-day mortality in fluconazole non-susceptible infection included reduced serum bicarbonate, thrombocytopenia, recent exposure to the macrolide/tetracycline/clindamycin antibiotics, elevated blood urea nitrogen, and lack of recent outpatient surgery. In the propensity-matched comparison, 30-day mortality between the 2 groups was not statistically significant: 26.6% for episodes with susceptible fluconazole isolates vs 24.9% for non-susceptible episodes (139/522 vs 65/251; P = 0.60). Conclusion and Relevance: Several host-derived physiological markers and recent exposure to protein synthesis inhibitor antibiotics were independent variables associated with 30-day mortality in patients with non-susceptible serious Candida sp. infections. This information may guide clinicians toward strategies to improve the clinical outcomes of these patients.Keywords
This publication has 24 references indexed in Scilit:
- Population-based longitudinal study over two decades of Candida and Candida-like species bloodstream infection reveals gender and species differences in mortality, recurrence and resistanceJournal of Infection, 2025
- Impact of Fluconazole Resistance on the Outcomes of Patients With Candida parapsilosis Bloodstream Infections: A Retrospective Multicenter StudyClinical Infectious Diseases, 2025
- Attributable mortality of candidemia – Results from the ECMM Candida III multinational European Observational Cohort StudyJournal of Infection, 2024
- A biological and genomic comparison of a drug-resistant and a drug-susceptible strain of Candida auris isolated from Beijing, ChinaVirulence, 2021
- Are the Statins promising antifungal agents against invasive candidiasis?Biomedicine & Pharmacotherapy, 2019
- Antifungal drug resistance: evolution, mechanisms and impactCurrent Opinion in Microbiology, 2018
- The updated Charlson comorbidity index is a useful predictor of mortality in patients with Staphylococcus aureus bacteraemiaEpidemiology and Infection, 2018
- Epidemiology and antifungal susceptibility of candidemia isolates of non- albicans Candida species from cancer patientsEmerging Microbes & Infections, 2017
- Risk Factors for Mortality in Patients with Pseudomonas aeruginosa Bacteremia: Clinical Impact of Antimicrobial Resistance on OutcomeMicrobial Drug Resistance, 2011
- Changes of virulence factors accompanying the phenomenon of induced fluconazole resistance in Candida albicansMycoses, 2000